Phase III SACHI trial (CTR20211441) is a randomized, two-arm, open-label, multi-center study evaluating the efficacy and safety of savolitinib plus osimertinib versus chemotherapy in NSCLC patients from China with MET amplification who has progressed after first- to third-generation EGFR–TKI therapy and has already begun its recruitment in multiple centers. This evidence concerns the gene MET and non-small cell lung carcinoma.